- $465.84m
- $288.98m
- 29
- 17
- 50
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.75 | ||
| Price to Tang. Book | 2.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -71.24% | ||
| Return on Equity | -84.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 9.06 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Directors
- Rainer Erdtmann PRE (57)
- Ramses Erdtmann PRE
- Thomas Butler CEO (40)
- Franco Valle CFO (40)
- Sunny Ryan EVF (51)
- Thorsten Kirschberg EVP (51)
- Heow Tan CTO
- Naomi Cretcher VOP
- Eric Aguiar IND (59)
- Bihua Chen IND (53)
- Michael Hitchcock IND (71)
- John Kwon IND (49)
- Sumita Ray IND (47)
- Sotirios Stergiopoulos IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 9th, 2017
- Public Since
- April 16th, 2021
- No. of Shareholders
- 40
- No. of Employees
- 103
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 35,889,360
- Address
- 900 Middlefield Road, 4Th Floor, REDWOOD CITY, 94063
- Web
- https://www.biomeafusion.com/
- Phone
- +1 6509809099
- Contact
- Chunyi Zhao
- Auditors
- Deloitte & Touche LLP
Upcoming Events for BMEA
Similar to BMEA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:04 UTC, shares in Biomea Fusion are trading at $12.98. This share price information is delayed by 15 minutes.
Shares in Biomea Fusion last closed at $12.98 and the price had moved by -49.77% over the past 365 days. In terms of relative price strength the Biomea Fusion share price has underperformed the S&P500 Index by -59.43% over the past year.
The overall consensus recommendation for Biomea Fusion is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biomea Fusion does not currently pay a dividend.
Biomea Fusion does not currently pay a dividend.
Biomea Fusion does not currently pay a dividend.
To buy shares in Biomea Fusion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $12.98, shares in Biomea Fusion had a market capitalisation of $465.84m.
Here are the trading details for Biomea Fusion:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BMEA
Based on an overall assessment of its quality, value and momentum Biomea Fusion is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biomea Fusion is $54.43. That is 319.34% above the last closing price of $12.98.
Analysts covering Biomea Fusion currently have a consensus Earnings Per Share (EPS) forecast of -$4.07 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomea Fusion. Over the past six months, its share price has outperformed the S&P500 Index by +4.14%.
As of the last closing price of $12.98, shares in Biomea Fusion were trading -16.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biomea Fusion PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biomea Fusion's management team is headed by:
- Rainer Erdtmann - PRE
- Ramses Erdtmann - PRE
- Thomas Butler - CEO
- Franco Valle - CFO
- Sunny Ryan - EVF
- Thorsten Kirschberg - EVP
- Heow Tan - CTO
- Naomi Cretcher - VOP
- Eric Aguiar - IND
- Bihua Chen - IND
- Michael Hitchcock - IND
- John Kwon - IND
- Sumita Ray - IND
- Sotirios Stergiopoulos - IND